Diffuse Large B-Cell Lymphoma Medical Services in China

Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma, accounting for approximately 30–40% of cases globally. It is an aggressive, monoclonal B-cell malignancy characterized by rapid proliferation of large, atypical lymphoid cells infiltrating lymph nodes or extranodal sites. Diagnosis relies on histopathology, immunohistochemistry (e.g., CD20+, CD79a+, PAX5+), and molecular profiling—including cell-of-origin classification (GCB vs. ABC subtypes) and detection of high-risk genetic alterations (e.g., MYC/BCL2 double-expression or double-hit status). First-line therapy typically involves R-CHOP immunochemotherapy (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone), with response assessed via PET-CT. For relapsed or refractory disease, options include salvage chemotherapy, autologous stem cell transplantation, bispecific antibodies (e.g., glofitamab), CAR-T cell therapy (e.g., cilta-cel, brexucabtagene autoleucel), and novel agents targeting BTK or BCL2 pathways. Prognosis varies significantly based on IPI score, molecular features, and treatment response—5-year overall survival ranges from 60–80% in fit patients receiving standard care.

China offers compelling advantages for DLBCL management: its top-tier oncology centers—such as Peking University Cancer Hospital and Fudan University Shanghai Cancer Center—host internationally trained hematologists and participate in global clinical trials. Advanced diagnostics (next-generation sequencing, digital pathology) and therapeutics—including FDA- and NMPA-approved CAR-T products—are widely accessible. Real-world data demonstrate comparable progression-free survival to Western benchmarks, particularly in high-risk cohorts treated with integrated multimodal strategies. Crucially, comprehensive care—including outpatient monitoring, supportive services, and follow-up—is delivered at approximately 40–60% lower cost than in the US or Western Europe, without compromising quality or regulatory oversight. As a dedicated medical tourism agency, we facilitate seamless access for international patients: verifying hospital accreditation, coordinating specialist consultations, securing transparent, all-inclusive pricing packages, and providing end-to-end support—from visa assistance and travel logistics to language interpretation and post-treatment coordination.

Treatment Options & Itemized Cost Breakdown: Diffuse Large B-Cell Lymphoma (DLBCL)

Non-Surgical/Medical Therapies

*Target Criteria*: Newly diagnosed, fit patients (ECOG 0–2), no CNS involvement; relapsed/refractory cases after prior chemoimmunotherapy.

• •R-CHOP Regimen (Standard First-Line)

- Cyclophosphamide (750 mg/m² IV): $110–$140 per dose - Doxorubicin (50 mg/m² IV): $190–$230 per dose - Vincristine (1 $85–$110 per dose - Prednisone (100 mg $8–$12 per cycle - *Supportive Care*: G-CSF (filgrastim, 300 µg SC): $140–$180 per injection (as needed); antiemetics, hydration, monitoring

• •Diagnostic & Monitoring Labs/Exams (Per, LFTs, renal panel, LDH, β2-microglobulin: $45–$65

- Bone marrow biopsy (diagnostic): $290–$360 - Flow cytometry + IHC on tissue: $220–$280

• •Diagnostic Core Biopsy (Lymph Node or Extranodal Site)

- Pre-op workup (CBC, coagulation, ECG, chest X-ray): $130–$170

• •Therapeutic Procedures

- Debulking surgery (rare, only for life-threatening GI obstruction or airway compromise): $$3,400 (including anesthesia, OR time, pathology) - Pre-op workup (enhanced CT/MRI): $420–$590

• •High-Risk (Double-Hit/Triple-Hit) DLBCL: DA-EPOCH-R regimen — 6 cycles, extended infusion$12,800–$16,500
• •Relapsed/Refractory DLBCL (eligible for CAR-T):

- Bridging chemo + lymphodepletion (fludarabine/cyclophosphamide): $1,9400 - Inpatient monitoring (28-day minimum): $4,200–$6,100

• •CNS Involvement: High-dose methotrexate (IV) + cytarabine + intrathecal therapy — 4–6 cycles: $7,300–$9,600

Quick Selection Guide

• •Fit <65 years, standard-risk: R-CHOP ($12,400–$15,800 total)
• •Age ≥75 or significant comorbidities (e.g., severe CAD, CKD): R-miniCHOP or R-GemOx — lower toxicity, $7,200–$9,500
• •Budget-constrained (<$5,000): Generic rituximab + CHOP (non-biosimilar doxorubicin — $4,100–$5,300, with reduced supportive care
• •Relapsed/refractory with adequate organ function: CAR-T preferred if accessible; otherwise, polatuzumab + bendamustine + rituximab ($8,900–$11,300)
• •CNS-positive or bulky disease (>10 cm): Immediate high-dose systemic + intrathecal therapy — $10,600–$13,900